Muhammad Salim

Muhammad Salim

Saskatchewan Cancer Agency - Saskatoon / Canada
Medical and Health Sciences / Hematology
AD Scientific Index ID: 4789507
-
person_outline Muhammad Salim's MOST POPULAR ARTICLES
1-) The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group MD Seftel, J Kuruvilla, T Kouroukis, V Banerji, G Fraser, M Crump, ... Leukemia & lymphoma 58 (6), 1358-1365, 2017 312017
2-) Diagnosis and management of spinal metastasis of glioblastoma P Tai, A Dubey, M Salim, K Vu, R Koul Canadian Journal of Neurological Sciences 42 (6), 410-413, 2015 122015
3-) N0337: Phase II study of capecitabine in combination with vinorelbine and trastuzumab for the first or second treatment of HER2+ metastatic breast cancer W Tan, J Allred, M Salim, P Flynn, JW Kugler, PJ Stella, M Wiesenfeld, ... Journal of Clinical Oncology 27 (15S), 1020-1020, 2009 22009
4-) Lapatinib or trastuzumab with taxane therapy as first-line treatment in metastatic breast cancer (MBC): A biomarker analysis in NCIC CTG MA. 31.WR Parulekar, S Aparicio, JAW Chapman, D Gao, LE Shepherd, ...Journal of Clinical Oncology 32 (15_suppl), 601-601, 201412014
5-) Resolution of pulmonary metastases after surgical removal of clear cell meningiomaA Dubey, HI Chalchal, M Salim, R KoulHong Kong J Radiol 14, 29-34, 201112011